Creativity, insight, and questionable poots.
The ants seem to like it. #nobot follows plz.
Mostly talking to myself, or others who think like me.
| Pronouns | [Subject-pronoun] / [Reflexive] |
| Twitter Alt | https://twitter.com/ultimape |
| Blog | @[email protected] |
| Bluesky | https://bsky.app/profile/ultimape.bsky.wovensoup.com |
Happy to announce that patreon has approved my account at the current funding tier.
With this, I have successfully achieved "autistic citizen scientist bootstrapped a crowd-sourced basic income by eating dog shit"
My next life goal is my own lab.
https://glif.app/@UltimApe/runs/xuiveqktv82cdwsoaz214nen
Thank you everyone, especially @rw & moon
The [[Agora]] is a free knowledge commons that complements social networks:
Sorry I haven't been very active here.
I've been really enjoying Bluesky though, so if you happen to have an account there you're welcome to follow me.
If you want to understand my content better consider this thread from a year ago about sperm banks and animal husbandry.
https://bsky.app/profile/ultimape.bsky.wovensoup.com/post/3jvxwii3jy22m
The absolutely infuriating thing about Tumblr potentially starting to silently sell off your posts unless you affirmatively check a deeply-hidden opt-out box you can only find out about through word of mouth is, if I bring up my *own* Tumblr and try to scroll back more than a few posts, it stops me literally saying "Stop: Classified". So I don't get access to my posts, but OpenAI does.
If you have a Tumblr and you'd like them to not share the stuff you post with predictive algorithmic generators^W^W^W^H "AI", there's now a toggle in each blog's settings that tells them not to: https://www.tumblr.com/yutaleks/743510553034719232
Looks like @darius made it not suck anymore! https://github.com/mastodon/mastodon/pull/22048
Thanks!
Is it still a thing where If I add people to lists It also forces me to follow them in the home feed?
The entire reason I used lists on twitter is to remove noise from home feed there.
Friendly reminder that if you are feeling sad this winter that you might be under the effects of low vitamin D. Vitamin D + Omega 3s + Tryptophan has been shown to be effective at boosting serotonin: https://www.sciencedaily.com/releases/2014/02/140226110836.htm
https://www.sciencedaily.com/releases/2015/02/150225094109.htm
In addition, there is the possibility that those 3 nutrients play a role in helping to avoid non-alcoholic fatty liver disease thru action on the microbiome. https://www.sciencedirect.com/science/article/pii/S2211124718304856
Serotonin and vitamin D have been proposed to play a role in autism, however, no causal mechanism has been established. Now, researchers show that serotonin, oxytocin, and vasopressin, three brain hormones that affect social behavior related to autism, are all activated by vitamin D hormone. Supplementation with vitamin D and tryptophan would be a practical and affordable solution to help prevent autism and possibly ameliorate some symptoms of the disorder.
Jesus fuck
I wrote a paper in 2019 https://doi.org/10.1136/bmjopen-2019-034306
And the whole point of my paper is that drug repurposing doesn't save effort/cost
Khan et al cites me, saying:
> It is common for pharmaceutical companies to trial medicines for indications beyond the initially approved indication (Reference Carlisle, Doussau and Kimmelman). This significantly reduces the drug development timeline and saves cost.
https://doi.org/10.1017/S0266462323000491
Objectives After regulatory approval, drug companies, public funding agencies and academic researchers often pursue trials aimed at extending the uses of a new drug by testing it in new non-approved indications. Patient burden and clinical impact of such research are not well understood. Design and setting We conducted a retrospective cohort study of postapproval clinical trials launched within 5βyears after the drugβs first approval, testing anticancer drugs in monotherapy in indications that were first pursued after a drugβs first Food and Drug Administration (FDA) license, for all 12 anticancer drugs approved between 2005 and 2007. FDA, Medline and Embase search date 2019 February 12. Primary and secondary outcome measures Our primary objective was to measure burden and clinical impact for patients enrolling in these trials. Each trial was sorted into a βtrajectoryβ defined by the drug and cancer indication. The risk was operationalised by proportions of grade 3β4 severe adverse events and deaths. The clinical impact was measured by estimating the proportion of patients participating in trajectories that resulted in FDA approval, uptake into National Comprehensive Cancer Network (NCCN) clinical practice guidelines or advancement to randomised controlled trials within 8βyears. Results Our search captured 104 published trials exploring monotherapy, including 69 unique trajectories. In total, trials in our sample enrolled 4699 patients. Grade 3β4 adverse events were experienced by 19.6% of patients; grade 5 events were experienced by 2.8% of patients. None of the trajectories launched after initial drug approval received FDA approval. Five trajectories were recommended by the NCCN within 8βyears of the first trial within that trajectory. Eleven trajectories were advanced to randomised controlled testing. Conclusions The challenges associated with unlocking new applications for drugs that first received approval from 2005 to 2007 were similar to those for developing new drugs altogether. Our findings can help inform priority setting in research and provide a basis for calibrating expectations when considering enrolment in label-extending trials.
What can end up happening is that if you and said 'as-if' actor disagree on a point.
You may want to reposition the discussion back to the 'real world' and reject their imagined reality based on a disagreement on how things could have proceeded.
This suddenly cause an inherent argument, because at a fundamental level we are suddenly playing a game of "imagine this to be true, now we can imagine how it can be true in the real world". hence it feeling like sophistry.
In that case, bow out.
In #Flancia we'll meet
mcc
Unnamed TNG skant beefcake